CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 59 enrolled
Drug / intervention
MEDI4920 3 mg +7 morebiological
Likely dose
MEDI4920 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02151110
NCT02151110Phase 1Completed
CompareCT.gov

A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults

MedImmune LLC·interventional·Posted May 30, 2014·Updated Feb 15, 2019

In Brief

A Phase 1 clinical trial evaluating MEDI4920 3 mg, MEDI4920 10 mg, and 6 other interventions for Healthy Volunteer. Completed, enrolled 59 participants across 1 site.

Detailed Summary

Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 30, 2014
Enrollment StartMay 27, 2014
Primary CompletionMay 9, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.1 years ago

Interventions

MEDI4920 3 mgbiological

Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.

MEDI4920 10 mgbiological

Participants received single IV dose of MEDI4920 10 mg infused on Day 1.

MEDI4920 30 mgbiological

Participants received single IV dose of MEDI4920 30 mg infused on Day 1.

MEDI4920 100 mgbiological

Participants received single IV dose of MEDI4920 100 mg infused on Day 1.

MEDI4920 300 mgbiological

Participants received single IV dose of MEDI4920 300 mg infused on Day 1.

MEDI4920 1000 mgbiological

Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.

MEDI4920 3000 mgbiological

Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.

Placeboother

Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.